Portola Pharmaceuticals, Inc.
270 E. Grand Avenue
South San Francisco
California
94080
United States
Tel: 650.246.7000
Fax: 650.246.7376
Website: http://www.portola.com/
Email: contact@portola.com
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
Stock Exchange: NASDAQ
Stock Symbol: PTLA
269 articles about Portola Pharmaceuticals, Inc.
-
Portola To Announce Third Quarter 2016 Financial Results And Host Conference Call On Monday, November 7
10/31/2016
-
Portola Submits New Drug Application To FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients
10/25/2016
-
Portola Announces Upcoming Data Presentations On Andexxa (Andexanet Alfa) At Neurocritical Care Society 2016 Annual Meeting
9/13/2016
-
Portola Announces Interim Results From Ongoing Phase IIIb/IV ANNEXXA-4 Study Of Factor Xa Inhibitor Antidote Andexxa (Andexanet Alfa) In Patients With Acute Major Bleeding
8/30/2016
-
Portola Announces Presentation Of Interim Results From Phase IIIb/IV ANNEXA-4 Study Of Andexxa (Andexanet Alfa) At European Society of Cardiology 2016 Congress
8/26/2016
-
Portola Announces Validation Of Marketing Authorization Application (MAA) By EMA For Indexxa (Andexanet Alfa), A Factor Xa Inhibitor Antidote
8/19/2016
-
Bay Area's Portola Plummets as FDA Rejects AndexXa NDA
8/19/2016
-
Portola Reports Second Quarter 2016 Financial Results And Provides Corporate Update
8/10/2016
-
Portola To Announce Second Quarter 2016 Financial Results And Host Conference Call On Tuesday, August 9
8/3/2016
-
10 Biotech Stocks that Could Blow Up in Q3
7/6/2016
-
5 Biotech Stocks at Bargain Basement Prices
6/22/2016
-
Portola Announces Full Results Of Phase 3 APEX Study Of Betrixaban Presented At International Society On Thrombosis And Haemostasis (ISTH) Meeting
5/27/2016
-
Portola Reports First Quarter 2016 Financial Results And Provides Corporate Update
5/6/2016
-
Top 5 Biotech Winners and Losers of Q1 2016
4/1/2016
-
Portola Craters as Long-Acting Blood Thinner Betrixaban Missed Primary Goal in Phase III Study
3/25/2016
-
Three Biotechs Face Near-Term FDA Decisions
3/22/2016
-
Portola Announces Biologics License Application For Andexanet Alfa Accepted For Review By FDA
2/18/2016
-
Three Underperforming Biopharma Companies Worth Looking At
2/15/2016
-
Bay Area's Portola Wrangles Andexanet Alfa Deal Worth $120 Million from Bristol-Myers Squibb, Pfizer
2/1/2016
-
Portola To Webcast Corporate Update On January 12, 2016
1/8/2016